{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:24:58Z","timestamp":1740176698442,"version":"3.37.3"},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T00:00:00Z","timestamp":1706918400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100029611","name":"Association of Schools and Colleges of Optometry","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100029611","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","advancesradonc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Radiation Oncology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.adro.2024.101468","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T17:09:07Z","timestamp":1707412147000},"page":"101468","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Predictors of Toxicity in a Randomized Study of Consolidation Chemoradiation Versus Observation After First Line Chemotherapy in Advanced Gall Bladder Cancers"],"prefix":"10.1016","volume":"9","author":[{"given":"Sushma","family":"Agrawal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anshika","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishwas","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahul","family":"Rahul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prabhakar","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajan","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.adro.2024.101468_bib0001","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.adro.2024.101468_bib0002","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.adro.2024.101468_bib0003","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.adro.2024.101468_bib0004","doi-asserted-by":"crossref","first-page":"59","DOI":"10.6004\/jnccn.2017.7067","article-title":"Chemoradiotherapy versus chemotherapy alone for unresected nonmetastatic gallbladder cancer: National practice patterns and outcomes","volume":"16","author":"Verma","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.adro.2024.101468_bib0005","doi-asserted-by":"crossref","first-page":"577","DOI":"10.4103\/ijc.IJC_1145_20","article-title":"Consolidation Chemo-radiation improves survival in responders to first line chemotherapy (CT) in locally advanced GBC (LA-GBC)","volume":"59","author":"Agrawal","year":"2022","journal-title":"Indian Journal of Cancer"},{"key":"10.1016\/j.adro.2024.101468_bib0006","doi-asserted-by":"crossref","first-page":"88","DOI":"10.18203\/2349-3259.ijct20230055","article-title":"A randomized study of consolidation chemoradiation (CTRT) versus observation after first-line chemotherapy (CT) in advanced gall bladder cancers (GBC): RACE-GB Study: Trial Protocol","volume":"10","author":"Agrawal","year":"2023","journal-title":"Int J Clin Trials"},{"issue":"Suppl 16","key":"10.1016\/j.adro.2024.101468_bib0007","article-title":"A randomized study of consolidation chemoradiation (CTRT) versus observation after first-line chemotherapy (CT) in advanced gall bladder cancers (GBC): RACE-GB study","volume":"41","author":"Agrawal","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2024.101468_bib0008","doi-asserted-by":"crossref","first-page":"955","DOI":"10.21873\/anticanres.11404","article-title":"Clinical target volume in biliary carcinoma: A systematic review of pathological studies","volume":"37","author":"Marinelli","year":"2017","journal-title":"Anticancer Res"},{"key":"10.1016\/j.adro.2024.101468_bib0009","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of cancer (EORTC)","volume":"31","author":"Cox","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2024.101468_bib0010","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/0360-3016(94)00418-K","article-title":"Hepatic toxicity resulting from cancer treatment","volume":"31","author":"Lawrence","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"Suppl 3","key":"10.1016\/j.adro.2024.101468_bib0011","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ijrobp.2009.06.092","article-title":"Radiation-associated liver injury","volume":"76","author":"Pan","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2024.101468_bib0012","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ijrobp.2006.08.015","article-title":"Dose-volumetric parameters predicting radiation-induced hepatic toxicity in unresectable hepatocellular carcinoma patients treated with three-dimensional conformal radiotherapy","volume":"67","author":"Kim","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2024.101468_bib0013","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ijrobp.2005.12.031","article-title":"Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: The risk factors and hepatic radiation tolerance","volume":"65","author":"Liang","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2024.101468_bib0014","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.prro.2016.10.003","article-title":"Assessment of hepatic function decline after stereotactic body radiation therapy for primary liver cancer","volume":"7","author":"Toesca","year":"2017","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.adro.2024.101468_bib0015","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1440-1746.1997.tb00356.x","article-title":"Duodenal erosions and ulcers in patients with pancreato-biliary obstruction","volume":"12","author":"Abbas","year":"1997","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.adro.2024.101468_bib0016","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.21037\/jgo-20-245","article-title":"Chemoradiotherapy for patients with locally advanced or unresectable extra-hepatic biliary cancer","volume":"11","author":"Jethwa","year":"2020","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.adro.2024.101468_bib0017","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.2011.39.1953","article-title":"Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: The ARTIST trial","volume":"30","author":"Lee","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2024.101468_bib0018","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00280-016-3143-2","article-title":"A pilot study of concurrent chemoradiotherapy with gemcitabine and cisplatin in patients with locally advanced biliary tract cancer","volume":"78","author":"Kyong","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.adro.2024.101468_bib0019","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1245\/s10434-017-6131-9","article-title":"Chemoradiation therapy for unresected extrahepatic cholangiocarcinoma: A propensity score-matched analysis","volume":"24","author":"Torgeson","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.adro.2024.101468_bib0020","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1016\/j.ejca.2014.08.013","article-title":"Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Federation Francophone de Cancerologie Digestive 9902 phase II randomised study","volume":"50","author":"Phelip","year":"2014","journal-title":"Eur J Cancer"}],"container-title":["Advances in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109424000319?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109424000319?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T15:18:51Z","timestamp":1715786331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452109424000319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2452109424000319"],"URL":"https:\/\/doi.org\/10.1016\/j.adro.2024.101468","relation":{},"ISSN":["2452-1094"],"issn-type":[{"type":"print","value":"2452-1094"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of Toxicity in a Randomized Study of Consolidation Chemoradiation Versus Observation After First Line Chemotherapy in Advanced Gall Bladder Cancers","name":"articletitle","label":"Article Title"},{"value":"Advances in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.adro.2024.101468","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101468"}}